


Thalidomide-4-O-C10-NH2

| | |
|--------------------|---|
| Cat. No.: | HY-130963 |
| CAS No.: | 1957236-08-6 |
| Molecular Formula: | C ₂₃ H ₃₁ N ₃ O ₅ |
| Molecular Weight: | 429.51 |
| Target: | E3 Ligase Ligand-Linker Conjugates; Apoptosis; Autophagy |
| Pathway: | PROTAC; Apoptosis; Autophagy |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|---------------------------|--|
| Description | Thalidomide-4-O-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology ^[1] . |
| IC ₅₀ & Target | Cereblon |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11.

[2]. Nalawansa DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-1008.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA